no icon
no icon
amc icon

Iti Pharma And Healthcare Fund - Regular Plan - Growth

Equity | Sector Specific - Pharma

(NAV as of 16/04/2024)
13.55 (0.24)

3Y Returns

NA

Min SIP

500

Min Lumpsum

5000

Expense Ratio

2.34%

Fund Size

143 Cr

Inception Date

08-Nov-21

Fund Manager

Rohan Korde

Exit Load

1% on or before 12M, Nil after 12M.

Wealthzi View

Overall Fund Zi Tag

Asset Allocation

Equity

97.76%

Debt & Others

2.24%

Market Cap Allocation

Large Cap

36.78%

Mid Cap

31.73%

Small Cap

29.25%

Other Cap

2.24%

Sector Allocation

Pharmaceuticals

77.30%

Health Care

18.17%

Chemicals

2.96%

Cash/Deposits/Margins/Treps/Repo/Swaps

0.82%

Fertilizers

0.75%

Top Ten Holdings

Sun Pharmaceutical Industries Ltd

15.49%

Aurobindo Pharma Ltd

5.45%

Max Healthcare Institute Ltd

5.30%

Lupin Ltd

5.19%

Dr. Reddy'S Laboratories Ltd

5.16%

Investment Objective

The Investment Objective Of The Scheme Is To Seek To Generate Long Term Capital Appreciation Throughinvesting In Equity And Equity Related Securities Of Companies Engaged In Pharma And Healthcare.However, There Can Be No Assurance Or Guarantee That The Investment Objective Of The Scheme Would Be Achieved.

Fund House Detail

AMC Name

ITI Asset Management Limited

Address

Naman Midtown, A - Wing,21st Floor, Senapati Bapat Marg, Elphinstone RoadMumbai - 400 013

BUILD WEALTH WITH CONFIDENCE

no iconno iconno iconno icon
no icon

BSE Member code: 58371

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.
get on play storeget on app store

Wealthzi Investment Advisers (A division of Lime Internet Private Limited)

[CIN: U74999DL2017PTC310507] [PAN: AADCL2103M] [GSTIN: 07AADCL2103M1ZP]

[SEBI Registered Name: Lime Internet Private Limited] [SEBI RIA Registration No: INA000018133] [BASL Member ID: 2014] [Type of Registration: Non-Individual] [Validity of Registration: Perpetual] [Registered Address: Flat No. 603, 6th Floor, Kanchenjunga Building, 18 Barakhamba Road, New Delhi - 110001] [Principal Officer: Jyoti Prakash Nayak, Email: [email protected]] [Compliance Officer: Harshit Singh, Email: [email protected]] [Grievance Officer: Sahad PV, Email: [email protected]]

[SEBI Regional Office Address: Securities and Exchange Board of India, NBCC Complex, Office Tower-1, 8th Floor, Plate B, East Kidwai Nagar, New Delhi - 110023, Ph: 011-69012998, Email: [email protected]]

Disclaimers:

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, membership of BASL and certification from National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The information is only for consumption by the client and such material should not be redistributed.